We found that high DCLK1 and IL-6 expression predicted shorter relapse-free survival (RFS) in TNBC (n = 392) but not in luminal A (n = 522), luminal B (n = 332) and HER2 (n = 315) subtypes, which suggested the dominant roles of DCLK1 and IL-6 in TNBC tumor recurrence (Fig. 6a, b). Here, DCLK1 is linked to neoplasm.